TLR8 Antibody

COA

级别和纯度:

见COA

应用:

IF/ICC
IHC
WB

宿主种属: 兔(Rabbit)
种属反应性: 人(Human), 大鼠(Rat), 小鼠(Mouse), 猪(Pig)
亚型: Rabbit IgG
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab131537-10μl	10μl	现货
Ab131537-50μl	50μL	现货
Ab131537-100μl	100μL	现货
Ab131537-1ml	1ml	期货

查看相关系列

点击查看靶蛋白信息: TLR8

Accession#:Q9NR97 (1) Gene ID:51311 (1) TLR8 (1)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	TLR8 Antibody
别名	Toll样受体8(TLR8)多克隆抗体 \| TLR8 抗体
英文别名	CD 288 antibody \| CD288 antibody \| CD288 antigen antibody \| MGC119599 antibody \| MGC119600 antibody \| TLR 8 antibody \| Tlr8 antibody \| TLR8_HUMAN antibody \| Toll like receptor 8 antibody \| Toll-like receptor 8 antibody \| TLR8 \| CD288 \| IMD98 \| TLR-8 \| hTL
规格或纯度	无载体, ExactAb™, 已验证, 高性能, 见COA
宿主种属	兔(Rabbit)
特异性	TLR8
种属反应性	人(Human),大鼠(Rat),小鼠(Mouse),猪(Pig)
免疫原	Recombinant TLR8 expressed in E.coli (AA 844-1039)
阳性对照	WB: HeLa, Hep G2, NIH/3T3 and C6 cell lysates. IHC: Human spleen, colon tissues. ICC/IF: HeLa cells.
偶联	Unconjugated

产品属性

克隆类型	多克隆抗体
Format	Whole IgG
亚型	Rabbit IgG
SDS-PAGE	150 kDa
纯化方法	Antigen affinity purified + Protein A purified
物理外观	Liquid
储存缓冲液	10mM PBS, 50% Glycerol, 0.02% Sodium azide, pH 7.4
防腐剂	0.02% Sodium azide
浓度	见COA
储存温度	-20°C储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	4℃ 短期储存（1-2 周）。-20℃长期保存（24 个月）。收货后建议分装。避免冷冻/解冻循环。
分子类型	抗体

关联靶点（人）

TLR8 Tchem Toll 类受体 8(Toll-like receptor 8) (0 活性数据)

点击查看靶蛋白信息： TLR8

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Western Blot: TLR8 Antibody (Ab131537)

TLR8 Antibody (Ab131537) - Western Blot
All lanes: TLR8 Antibody (Ab131537) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 121 kDa
Observed band size: 150 kDa
Exposure time: 60.0 s

IF/ICC: TLR8 Antibody (Ab131537)

TLR8 Antibody (Ab131537) - IF/ICC
FITC staining on IF
Sample: Human HeLa cell
Primary Ab: 20 μg/mL TLR8 Antibody (Ab131537)
Second Ab: 2 μg/mL FITC-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody.

IHC: TLR8 Antibody (Ab131537)

TLR8 Antibody (Ab131537) - IHC
DAB staining on IHC
Samples: Human Spleen Tissue
Primary Ab: 20 μg/mL TLR8 Antibody (Ab131537)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody.

IHC: TLR8 Antibody (Ab131537)

TLR8 Antibody (Ab131537) - IHC
DAB staining on IHC
Samples: Human Colon Tissue
Primary Ab: 20 μg/mL TLR8 Antibody (Ab131537)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody.

应用

应用名称	稀释比例
IHC	5-20 µg/mL
IF/ICC	5-20 µg/mL
WB	0.01-2 µg/mL

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到3个结果

批号(Lot Number)	证书类型	货号
ZJ24F0404505	分析证书	Ab131537
ZJ24F0404506	分析证书	Ab131537
ZJ24F0404507	分析证书	Ab131537

技术文档和文章

冷冻样本的免疫组织化学染色实验方案（IHC-Fr）

Categories: 实验方案（Protocols）

探索主题:

重组抗体单克隆抗体 IHC 免疫组化冷冻切片

免疫组织化学染色的抗原修复方案

Categories: 实验方案（Protocols）

探索主题:

重组抗体单克隆抗体 IHC 免疫组化抗原修复

免疫肽封闭实验

Categories: 实验方案（Protocols）

探索主题:

多克隆抗体免疫肽封闭特异性结合

Immunopeptide blocking assay

Categories: 实验方案（Protocols）

探索主题:

Immunopeptideblocking PolyclonalAntibody SpecificBinding

Immunopeptide blocking assay

Categories: 实验方案（Protocols）

探索主题:

Immunopeptideblocking PolyclonalAntibody SpecificBinding

免疫荧光染色实验步骤（甲醇通透法）

Categories: 实验方案（Protocols）

探索主题:

冷冻切片免疫荧光染色组织切片甲醇通透 IF

Immunofluorescence Staining Protocol (Methanol permeabilization)

Categories: 实验方案（Protocols）

探索主题:

Frozen section IF Immunofluorescence staining Tissue section Methanol permeability

Immunofluorescence Staining Protocol (Methanol permeabilization)

Categories: 实验方案（Protocols）

探索主题:

Frozen section IF Immunofluorescence staining Tissue section Methanol permeability

引用文献

1. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C et al.. (2003) The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.. Genome Res, 13 (10): (2265-70). [PMID:12975309]
2. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848.. Nat Immunol, 3 (6): (499). [PMID:12032557]
3. Chan M, Hayashi T, Mathewson RD, Nour A, Hayashi Y, Yao S, Tawatao RI, Crain B, Tsigelny IF, Kouznetsova VL et al.. (2013) Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands.. J Med Chem, 56 (11): (4206-23). [PMID:23656327]
4. Doyle SL, Jefferies CA, Feighery C, O'Neill LA. (2007) Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.. J Biol Chem, 282 (51): (36953-60). [PMID:17932028]
5. Zhang S, Hu Z, Tanji H, Jiang S, Das N, Li J, Sakaniwa K, Jin J, Bian Y, Ohto U et al.. (2018) Small-molecule inhibition of TLR8 through stabilization of its resting state.. Nat Chem Biol, 14 (1): (58-64). [PMID:29155428]
6. Bou Karroum N, Moarbess G, Guichou JF, Bonnet PA, Patinote C, Bouharoun-Tayoun H, Chamat S, Cuq P, Diab-Assaf M, Kassab I et al.. (2019) Novel and Selective TLR7 Antagonists among the Imidazo[1,2-a]pyrazines, Imidazo[1,5-a]quinoxalines, and Pyrazolo[1,5-a]quinoxalines Series.. J Med Chem, 62 (15): (7015-7031). [PMID:31283223]
7. Mackman RL, Mish M, Chin G, Perry JK, Appleby T, Aktoudianakis V, Metobo S, Pyun P, Niu C, Daffis S et al.. (2020) Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.. J Med Chem, 63 (18): (10188-10203). [PMID:32407112]
8. Heinz LX, Lee J, Kapoor U, Kartnig F, Sedlyarov V, Papakostas K, César-Razquin A, Essletzbichler P, Goldmann U, Stefanovic A et al.. (2020) TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9.. Nature, 581 (7808): (316-322). [PMID:32433612]
9. Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu F, Tang JX, Putta MR, Cong Y, Trombino AF, Sullivan T, Agrawal S.. (2007) Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.. Proc Natl Acad Sci U S A, 104 (34): (13750-13755). [PMID:17698957] [10.1073/pnas.0706059104]
10. Kurimoto A, Hashimoto K, Nakamura T, Norimura K, Ogita H, Takaku H, Bonnert R, McInally T, Wada H, Isobe Y.. (2010) Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.. J Med Chem, 53 (7): (2964-2972). [PMID:20232824] [10.1021/jm100070n]
11. Shukla NM, Malladi SS, Mutz CA, Balakrishna R, David SA.. (2010) Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.. J Med Chem, 53 (11): (4450-4465). [PMID:20481492] [10.1021/jm100358c]
12. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN.. (2010) Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation.. Antimicrob Agents Chemother, 54 (2): (871-881). [PMID:19949061] [10.1128/aac.01246-09]
13. Shi C, Xiong Z, Chittepu P, Aldrich CC, Ohlfest JR, Ferguson DM.. (2012) Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.. ACS Med Chem Lett, 3 (6): (501-504). [PMID:22837811] [10.1021/ml300079e]
14. Kokatla HP, Sil D, Malladi SS, Balakrishna R, Hermanson AR, Fox LM, Wang X, Dixit A, David SA.. (2013) Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.. J Med Chem, 56 (17): (6871-6885). [PMID:23899291] [10.1021/jm400694d]
15. Roethle PA, McFadden RM, Yang H, Hrvatin P, Hui H, Graupe M, Gallagher B, Chao J, Hesselgesser J, Duatschek P, Zheng J, Lu B, Tumas DB, Perry J, Halcomb RL.. (2013) Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.. J Med Chem, 56 (18): (7324-7333). [PMID:23961878] [10.1021/jm400815m]
16. Watanabe M, Kasai M, Tomizawa H, Aoki M, Eiho K, Isobe Y, Asano S.. (2014) Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.. ACS Med Chem Lett, 5 (11): (1235-1239). [PMID:25408837] [10.1021/ml5003184]
17. Beesu M, Malladi SS, Fox LM, Jones CD, Dixit A, David SA.. (2014) Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.. J Med Chem, 57 (17): (7325-7341). [PMID:25102141] [10.1021/jm500701q]
18. Beesu M, Caruso G, Salyer AC, Khetani KK, Sil D, Weerasinghe M, Tanji H, Ohto U, Shimizu T, David SA.. (2015) Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.. J Med Chem, 58 (19): (7833-7849). [PMID:26351878] [10.1021/acs.jmedchem.5b01087]
19. McGowan DC, Herschke F, Pauwels F, Stoops B, Smyej I, Last S, Pieters S, Embrechts W, Khamlichi MD, Thoné T, Van Schoubroeck B, Mostmans W, Wuyts D, Verstappen D, Scholliers A, De Pooter D, Dhuyvetter D, Borghys H, Tuefferd M, Arnoult E, Hong J, Fanning G, Bollekens J, Urmaliya V, Teisman A, Horton H, Jonckers THM, Raboisson P.. (2017) Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.. J Med Chem, 60 (14): (6137-6151). [PMID:28671847] [10.1021/acs.jmedchem.7b00365]
20. Zhang L, Shi L, Soars SM, Kamps J, Yin H.. (2018) Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties.. J Med Chem, 61 (14): (5881-5899). [PMID:29870245] [10.1021/acs.jmedchem.7b01557]
21. Dolšak A, Švajger U, Lešnik S, Konc J, Gobec S, Sova M.. (2019) Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.. Eur J Med Chem, 179 (109-122). [PMID:31247373] [10.1016/j.ejmech.2019.06.030]
22. Jiang S, Tanji H, Yin K, Zhang S, Sakaniwa K, Huang J, Yang Y, Li J, Ohto U, Shimizu T, Yin H.. (2020) Rationally Designed Small-Molecule Inhibitors Targeting an Unconventional Pocket on the TLR8 Protein-Protein Interface.. J Med Chem, 63 (8): (4117-4132). [PMID:32233366] [10.1021/acs.jmedchem.9b02128]
23. Achek A, Shah M, Seo JY, Kwon HK, Gui X, Shin HJ, Cho EY, Lee BS, Kim DJ, Lee SH, Yoo TH, Kim MS, Choi S.. (2019) Linear and Rationally Designed Stapled Peptides Abrogate TLR4 Pathway and Relieve Inflammatory Symptoms in Rheumatoid Arthritis Rat Model.. J Med Chem, 62 (14): (6495-6511). [PMID:31283217] [10.1021/acs.jmedchem.9b00061]
24. Mukherjee A, Raychaudhuri D, Sinha BP, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A.. (2020) A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.. J Med Chem, 63 (9): (4776-4789). [PMID:32302115] [10.1021/acs.jmedchem.0c00011]
25. McGowan D, Herschke F, Pauwels F, Stoops B, Last S, Pieters S, Scholliers A, Thoné T, Van Schoubroeck B, De Pooter D, Mostmans W, Khamlichi MD, Embrechts W, Dhuyvetter D, Smyej I, Arnoult E, Demin S, Borghys H, Fanning G, Vlach J, Raboisson P.. (2016) Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.. J Med Chem, 59 (17): (7936-7949). [PMID:27513093] [10.1021/acs.jmedchem.6b00747]
26. Knoepfel T, Nimsgern P, Jacquier S, Bourrel M, Vangrevelinghe E, Glatthar R, Behnke D, Alper PB, Michellys PY, Deane J, Junt T, Zipfel G, Limonta S, Hawtin S, Andre C, Boulay T, Loetscher P, Faller M, Blank J, Feifel R, Betschart C.. (2020) Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.. J Med Chem, 63 (15): (8276-8295). [PMID:32786235] [10.1021/acs.jmedchem.0c00130]
27. Mussari CP, Dodd DS, Sreekantha RK, Pasunoori L, Wan H, Posy SL, Critton D, Ruepp S, Subramanian M, Watson A, Davies P, Schieven GL, Salter-Cid LM, Srivastava R, Tagore DM, Dudhgaonkar S, Poss MA, Carter PH, Dyckman AJ.. (2020) Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).. ACS Med Chem Lett, 11 (9): (1751-1758). [PMID:32944143] [10.1021/acsmedchemlett.0c00264]
28. Federico S,Pozzetti L,Papa A,Carullo G,Gemma S,Butini S,Campiani G,Relitti N. (2020) Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.. J Med Chem, 63 (22): (13466-13513). [PMID:32845153] [10.1021/acs.jmedchem.0c01049]
29. Du, X X, Poltorak, A A, Wei, Y Y and Beutler, B B.. (2000) Three novel mammalian toll-like receptors: gene structure, expression, and evolution.. European cytokine network, [PMID:11022119]
30. Chuang, T H TH and Ulevitch, R J RJ.. (2000) Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9.. European cytokine network, [PMID:11022120]
31. Dummer, R R and 5 more authors.. (2003) Imiquimod in basal cell carcinoma: how does it work?. The British journal of dermatology, [PMID:14616353]
32. Ross, Mark T MT and 281 more authors.. (2005) The DNA sequence of the human X chromosome.. Nature, (17): [PMID:15772651]
33. Qin, Jinzhong J and 12 more authors.. (2006) TLR8-mediated NF-kappaB and JNK activation are TAK1-independent and MEKK3-dependent.. The Journal of biological chemistry, (28): [PMID:16737960]
34. Nakajima, Toshiaki T and 6 more authors.. (2008) Natural selection in the TLR-related genes in the course of primate evolution.. Immunogenetics, [PMID:18810425]
35. Georgel, Philippe P, Macquin, Cécile C and Bahram, Seiamak S.. (2009) The heterogeneous allelic repertoire of human toll-like receptor (TLR) genes.. PloS one, (17): [PMID:19924287]
36. Tanji, Hiromi H, Ohto, Umeharu U, Shibata, Takuma T, Miyake, Kensuke K and Shimizu, Toshiyuki T.. (2013) Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands.. Science (New York, N.Y.), (22): [PMID:23520111]
37. Ishii, Noriko N, Funami, Kenji K, Tatematsu, Megumi M, Seya, Tsukasa T and Matsumoto, Misako M.. (2014) Endosomal localization of TLR8 confers distinctive proteolytic processing on human myeloid cells.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:25297876]
38. Tanji, Hiromi H and 5 more authors.. (2016) Autoinhibition and relief mechanism by the proteolytic processing of Toll-like receptor 8.. Proceedings of the National Academy of Sciences of the United States of America, (15): [PMID:26929371]
39. Evankovich, John J and 11 more authors.. (2019) Toll-Like Receptor 8 Stability is Regulated by Ring Finger 216 in response to circulating MicroRNAs.. American journal of respiratory cell and molecular biology, (6): [PMID:31385713]
40. Aluri, Jahnavi and 35 more authors.. (2020) Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain-of-function.. Blood, (23): [PMID:33512449]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

TLR8 Antibody

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

应用

质检证书（CoA,COO,BSE/TSE 和分析图谱)

技术文档和文章

相关产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器